blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1978362

EP1978362 - Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.07.2011
Database last updated on 31.08.2024
Most recent event   Tooltip01.07.2011Application deemed to be withdrawnpublished on 03.08.2011  [2011/31]
Applicant(s)For all designated states
Crossbeta Biosciences B.V.
Padualaan 8
3584 CH Utrecht / NL
[2010/46]
Former [2008/41]For all designated states
Crossbeta Biosciences B.V.
Heidelberglaan 100
3584 CX Utrecht / NL
Inventor(s)01 / Gebbink, Martijn Frans Ben Gerard
Zaadkorrel 34
3755 HL Eemnes / NL
02 / Bouma, Barend
Tappersgilde 3
3994 CE Houten / NL
03 / Kranenburg, Onno Wouter
Pretoriusstraat 91 III
1092 GD Amsterdam / NL
04 / Kroon, Louise Maria Johanna
Dominee van der Kraanplantsoen 22
3981 GN Bunnik / NL
 [2008/41]
Representative(s)Hatzmann, Martin
V.O.
Johan de Wittlaan 7
2517 JR Den Haag / NL
[N/P]
Former [2008/41]Hatzmann, Martin
Vereenigde Johan de Wittlaan 7
2517 JR Den Haag / NL
Application number, filing date08153132.908.07.2003
[2008/41]
Priority number, dateEP2002007779709.07.2002         Original published format: EP 02077797
[2008/41]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1978362
Date:08.10.2008
Language:EN
[2008/41]
Type: A3 Search report 
No.:EP1978362
Date:11.02.2009
[2009/07]
Search report(s)(Supplementary) European search report - dispatched on:EP13.01.2009
ClassificationIPC:A61K31/00, A61K31/7004, A61K31/195, A61K31/197, A61K31/198, A61K39/395, A61K38/49, G01N33/53, C12N9/72, A61P9/10, A61P3/10, A61P7/04, A61P35/00, A61P31/00, A61P37/00, A61P25/28, A61P25/16, A61M1/36, A61P7/02, A61P29/00, A61P25/08, G01N33/68
[2008/46]
CPC:
A61K31/7004 (EP,US); A61K31/00 (EP,US); A61K31/195 (EP,US);
A61K31/197 (EP,US); A61K31/198 (EP,US); A61K38/49 (EP,US);
A61P19/00 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P25/08 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/10 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/06 (EP); A61P7/00 (EP);
A61P7/02 (EP); A61P7/04 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07K16/18 (EP,US); C12N9/6459 (EP,US);
C12Y304/21069 (EP,US); G01N33/6854 (EP,US); G01N33/6896 (EP,US);
C07K2319/23 (EP,US); G01N2333/9726 (EP,US); G01N2800/042 (EP,US);
G01N2800/2821 (EP,US) (-)
Former IPC [2008/41]G01N33/53, C12N9/72, A61K31/197, A61K31/198, A61K31/7004, A61P9/10, A61P3/10, A61P7/04, A61P35/00, A61P31/00, A61P37/00, A61P25/28, A61P25/16, A61P7/02, A61P29/00, A61P25/08
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2008/41]
TitleGerman:Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität[2008/41]
English:Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity[2008/41]
French:Structure bêta croisée comportant des protéines à liaison d'amyloïde et procédés de détection de la structure bêta croisée, pour moduler des structures bêta croisées à formation fibrille et pour moduler la toxicité en mesurant la structure bêta croisée[2008/41]
Examination procedure20.03.2008Examination requested  [2008/41]
10.08.2009Amendment by applicant (claims and/or description)
01.10.2009Despatch of a communication from the examining division (Time limit: M06)
08.04.2010Reply to a communication from the examining division
28.07.2010Despatch of a communication from the examining division (Time limit: M06)
08.02.2011Application deemed to be withdrawn, date of legal effect  [2011/31]
16.03.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2011/31]
Parent application(s)   TooltipEP03762927.6  / EP1536778
Divisional application(s)EP10185187.1  / EP2322154
EP11153594.4  / EP2341348
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030762927) is  23.01.2006
Fees paidRenewal fee
20.03.2008Renewal fee patent year 03
20.03.2008Renewal fee patent year 04
20.03.2008Renewal fee patent year 05
31.03.2008Renewal fee patent year 06
15.07.2009Renewal fee patent year 07
15.07.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO9639834  (UNIV NEW YORK [US]) [A] * the whole document *;
 [A]US5750349  (SUZUKI NOBUHIRO [JP], et al) [A] * the whole document *;
 [A]US6037458  (HIRAI FUMIYASU [JP], et al) [A] * the whole document *;
 [A]US6136548  (ANDERSON STEPHEN [US]) [A] * the whole document *;
 [A]WO0112598  (UNIV COLUMBIA [US], et al) [A] * the whole document *;
 [X]  - CHAUHAN A ET AL, "Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein.", NEUROCHEMICAL RESEARCH FEB 1997, (199702), vol. 22, no. 2, ISSN 0364-3190, pages 227 - 232, XP002498010 [X] 1-5,53,54 * abstract * * page 228, paragraph "Thioflavin T Fluorescence Spectroscopy" *

DOI:   http://dx.doi.org/10.1023/A:1027379926976
 [X]  - ELGHETANY M T ET AL, "METHODS FOR STAINING AMYLOID IN TISSUES A REVIEW", STAIN TECHNOLOGY, WILLIAMS AND WILKINS, BALTIMORE, US, (19880101), vol. 63, no. 4, ISSN 0038-9153, pages 201 - 212, XP008051786 [X] 7 * abstract * * page 201, line 1 - page 202, line 16 *
 [X]  - KLUNK W E ET AL, "DEVELOPMENT OF SMALL MOLECULE PROBES FOR THE BETA-AMYLOID PROTEIN OF ALZHEIMER'S DISEASE", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, (19940101), vol. 15, no. 6, ISSN 0197-4580, pages 691 - 698, XP000602786 [X] 7,8,53,54 * abstract * * paragraphs "Binding Assay to Synthetic Abeta(10-43)" and "Discussion" * * figure 7 *

DOI:   http://dx.doi.org/10.1016/0197-4580(94)90050-7
 [DX]  - O'NUALLAIN BRIAN ET AL, "Conformational Abs recognizing a generic amyloid fibril epitope", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20020205), vol. 99, no. 3, ISSN 0027-8424, pages 1485 - 1490, XP002211263 [DX] 6-8,53-55 * abstract * * page 1487, column LEFT, line 9 - line 18 * * page 1488, column LEFT, line 13 - column RIGHT, line 18 * * page 1489, column RIGHT, line 25 - page 1490, column LEFT, line 2 * * figures 3,4 *

DOI:   http://dx.doi.org/10.1073/pnas.022662599
 [X]  - HUBBARD G B ET AL, "Spontaneous pancreatic islet amyloidosis in 40 baboons.", JOURNAL OF MEDICAL PRIMATOLOGY APR 2002, (200204), vol. 31, no. 2, ISSN 0047-2565, pages 84 - 90, XP002498011 [X] 7,8 * abstract *

DOI:   http://dx.doi.org/10.1034/j.1600-0684.2002.01020.x
Examination   - YUTANI K ET AL, "The process of amyloid-like fibril formation by methionine aminopeptidase from a hyperthermophile, Pyrococcus furiosus.", BIOCHEMISTRY 14 MAR 2000 LNKD- PUBMED:10704229, (20000314), vol. 39, no. 10, doi:10.1021/bi991406v, ISSN 0006-2960, pages 2769 - 2777, XP001128143

DOI:   http://dx.doi.org/10.1021/bi991406v
    - AKIYAMA H ET AL, "Inflammation and Alzheimer's disease.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (200005), Database accession no. NLM10858586
    - NEUROBIOLOGY OF AGING 2000 MAY-JUN LNKD- PUBMED:10858586, (200005), vol. 21, no. 3, ISSN 0197-4580, pages 383 - 421
by applicant   - BUCCIANTINI M; GIANNONI E; CHITI F ET AL., "Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases", NATURE, (2002), vol. 416, doi:doi:10.1038/416507a, pages 507 - 511, XP001174110

DOI:   http://dx.doi.org/10.1038/416507a
    - ROCHET JC; LANSBURY PT, JR., "Amyloid fibrillogenesis: themes and variations", CURR OPIN STRUCT BIOL., (2000), vol. 10, pages 60 - 68
    - CARMELIET P; BOUCHE A; DE CLERCQ C ET AL., "Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice", ANN N Y ACAD SCI., (1995), vol. 748, pages 367 - 381
    - CARMELIET P; COLLEN D., "Genetic analysis of the plasminogen and coagulation system in mice", HAEMOSTASIS, (1996), vol. 26, no. 4, pages 132 - 153
    - COLLEN D; LIJNEN HR, "Molecular basis of fibrinolysis, as relevant for thrombolytic therapy", THROMB HAEMOST., (1995), vol. 74, pages 167 - 171
    - LIJNEN HR; COLLEN D., "Mechanisms of physiological fibrinolysis", BAILLIERES CLIN HAEMATOL, (1995), vol. 8, pages 277 - 290
    - BOSMA PJ; RIJKEN DC; NIEUWENHUIZEN W., "Binding of tissue-type plasminogen activator to fibrinogen fragments", EUR J BIOCHEM., (1988), vol. 17, no. 2, pages 399 - 404
    - GRAILHE P; NIEUWENHUIZEN W; ANGLES-CANO E., "Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen", EUR J BIOCHEM., (1994), vol. 219, pages 961 - 967
    - NIEUWENHUIZEN W., "Fibrin-mediated plasminogen activation", ANN N Y ACAD SCI., (2001), vol. 936, doi:doi:10.1111/j.1749-6632.2001.tb03512.x, pages 237 - 246, XP055023314

DOI:   http://dx.doi.org/10.1111/j.1749-6632.2001.tb03512.x
    - YAKOVLEV S ET AL., "Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites", BIOCHEMISTRY, (2000), vol. 39, pages 15730 - 15741
    - BAKKER AH; WEENING-VERHOEFF EJ; VERHEIJEN JH., "The role of the lysyl binding site of tissue-type plasminogen activator in the interaction with a forming fibrin clot", J BIOL CHEM., (1995), vol. 270, doi:doi:10.1074/jbc.270.21.12355, pages 12355 - 12360, XP002319385

DOI:   http://dx.doi.org/10.1074/jbc.270.21.12355
    - DE MUNK GA ET AL., "Binding of tissue-type plasminogen activator to lysine, lysine analogues, and fibrin fragments", BIOCHEMISTRY, (1989), vol. 28, doi:doi:10.1021/bi00444a026, pages 7318 - 7325, XP002928602

DOI:   http://dx.doi.org/10.1021/bi00444a026
    - FLEURY V ET AL., "Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface", EUR J BIOCHEM., (1993), vol. 216, pages 549 - 556
    - HADDELAND U ET AL., "Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t-PA-catalysed plasminogen activation", THROMB HAEMOST., (1996), vol. 75, pages 326 - 331
    - HASAN AA; CHANG WS; BUDZYNSKI AZ., "Binding of fibrin fragments to one-chain and two- chain tissue-type plasminogen activator", BLOOD, (1992), vol. 79, pages 2313 - 2321
    - NIEUWENHUIZEN W ET AL., "Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator", BIOCHIM BIOPHYS ACTA, (1983), vol. 748, doi:doi:10.1016/0167-4838(83)90030-4, pages 86 - 92, XP025210540

DOI:   http://dx.doi.org/10.1016/0167-4838(83)90030-4
    - NIEUWENHUIZEN W ET AL., "Studies on the localization and accessibility of sites in fibrin which are involved in the acceleration of the activation of plasminogen by tissue-type plasminogen activator", ADV EXP MED BIOL., (1990), vol. 281, pages 83 - 91
    - NIEUWENHUIZEN W., "Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerisation", THROMB RES., (1994), vol. 75, doi:doi:10.1016/0049-3848(94)90248-8, pages 343 - 347, XP022881390

DOI:   http://dx.doi.org/10.1016/0049-3848(94)90248-8
    - SCHIELEN WJ ET AL., "The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen", BLOOD COAGUL FIBRINOLYSIS, (1991), vol. 2, pages 465 - 470
    - TSURUPA G; MEDVED L., "Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains", BIOCHEMISTRY, (2001), vol. 40, pages 801 - 808
    - YONEKAWA O; VOSKJIEN M; NIEUWENHUIZEN W., "Localization in the fibrinogen gamma- chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalysed activation of plasminogen", BIOCHEM J., (1992), vol. 283, no. 1, pages 187 - 191
    - BOBBINK IW ET AL., "Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation", BIOCHEM BIOPHYS RES COMMUN, (1997), vol. 240, pages 595 - 601
    - HU GF; RIORDAN JF., "Angiogenin enhances actin acceleration of plasminogen activation", BIOCHEM BIOPHYS RES COMMUN, (1993), vol. 197, doi:doi:10.1006/bbrc.1993.2533, pages 682 - 687, XP024766756

DOI:   http://dx.doi.org/10.1006/bbrc.1993.2533
    - KINGSTON IB; CASTRO MJ; ANDERSON S., "In vitro stimulation of tissue-type plasminogen activator byAlzheimer amyloid beta-peptide analogues", NAT MED., (1995), vol. 1, pages 138 - 142
    - LIND SE; SMITH CJ, "Actin accelerates plasmin generation by tissue plasminogen activator", J BIOL CHEM., (1991), vol. 266, pages 17673 - 17678
    - MACHOVICH R; OWEN WG., "Denatured proteins as cofactors for plasminogen activation", ARCH BIOCHEM BIOPHYS, (1997), vol. 344, doi:doi:10.1006/abbi.1997.0221, pages 343 - 349, XP002175284

DOI:   http://dx.doi.org/10.1006/abbi.1997.0221
    - MACHOVICH R ET AL., "Myosin as cofactor and substrate in fibrinolysis", FEBS LETT., (1997), vol. 407, doi:doi:10.1016/S0014-5793(97)00303-7, pages 93 - 96, XP002175285

DOI:   http://dx.doi.org/10.1016/S0014-5793(97)00303-7
    - MACHOVICH R ET AL., "Facilitation of plasminogen activation by denatured prothrombin", THROMB RES., (1999), vol. 94, pages 389 - 394
    - PARKKINEN J; HACKER J; KORHONEN TK., "Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by Escherichia coli S fimbriae associated with neonatal septicaemia and meningitis", THROMB HAEMOST., (1991), vol. 65, pages 483 - 486
    - PARKKINEN J; RAUVALA H., "Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin", J BIOL CHEM., (1991), vol. 266, pages 16730 - 16735
    - PRYZDIAL EL; BAJZAR L; NESHEIM ME., "Prothrombinase components can accelerate tissue plasminogen activator-catalyzed plasminogen activation", J BIOL CHEM., (1995), vol. 270, doi:doi:10.1074/jbc.270.30.17871, pages 17871 - 17877, XP002290381

DOI:   http://dx.doi.org/10.1074/jbc.270.30.17871
    - RADCLIFFE R; HEINZE T., "Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator", ARCH BIOCHEM BIOPHYS., (1981), vol. 211, doi:doi:10.1016/0003-9861(81)90512-9, pages 750 - 761, XP024757260

DOI:   http://dx.doi.org/10.1016/0003-9861(81)90512-9
    - SHENG S ET AL., "Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin", PROC NATL ACAD SCI USA., (1998), vol. 95, pages 499 - 504
    - SILVERSTEIN RL ET AL., "Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator", J CLIN INVEST., (1984), vol. 74, pages 1625 - 1633
    - STACK S; GONZALEZ-GRONOW M; PIZZO SV., "Regulation of plasminogen activation by components of the extracellular matrix", BIOCHEMISTRY, (1990), vol. 29, pages 4966 - 4970
    - WADA H; KUMEDA Y; OGASAWARA Z ET AL., "Stimulation of tissue type plasminogen activator by leukaemic cell homogenates", BLOOD COAGUL FIBRINOLYSIS, (1993), vol. 4, pages 591 - 597
    - CARRELL RW; GOOPTU B., "Conformational changes and disease--serpins, prions and Alzheimer's", CURR OPIN STRUCT BIOL., (1998), vol. 8, doi:doi:10.1016/S0959-440X(98)80101-2, pages 799 - 809, XP009012236

DOI:   http://dx.doi.org/10.1016/S0959-440X(98)80101-2
    - KRIEGER M; STERN DM., "Series introduction: multiligand receptors and human disease", J CLIN INVEST., (2001), vol. 108, pages 645 - 647
    - SCHMIDT AM ET AL., "Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis", CIRC RES., (1999), vol. 84, pages 489 - 497
    - SCHMIDT AM ET AL., "The biology of the receptor for advanced glycation end products and its ligands", BIOCHIM BIOPHYS ACTA, (2000), vol. 1498, doi:doi:10.1016/S0167-4889(00)00087-2, pages 99 - 111, XP004278211

DOI:   http://dx.doi.org/10.1016/S0167-4889(00)00087-2
    - SCHMIDT AM ET AL., "RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation", SEMIN THROMB HEMOST., (2000), vol. 26, pages 485 - 493
    - SCHMIDT AM ET AL., "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses", J CLIN INVEST., (2001), vol. 108, doi:doi:10.1172/JCI200114002, pages 949 - 955, XP002994307

DOI:   http://dx.doi.org/10.1172/JCI200114002
    - WELDON DT; MAGGIO JE; MANTYH PW., "New insights into the neuropathology and cell biology of Alzheimer's disease", GERIATRICS, (1997), vol. 52, no. 2, pages S13 - S16
    - YAN SD ET AL., "Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide", BIOCHIM BIOPHYS ACTA, (2000), vol. 1502, doi:doi:10.1016/S0925-4439(00)00041-7, pages 145 - 157, XP004276982

DOI:   http://dx.doi.org/10.1016/S0925-4439(00)00041-7
    - BALBACH JJ; ISHII Y; ANTZUTKIN ON ET AL., "Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR", BIOCHEMISTRY, (2000), vol. 39, pages 13748 - 13759
    - BOBBINK IW ET AL., "Effect of extracellular matrix glycation on endothelial cell adhesion and spreading: involvement of vitronectin", DIABETES, (1997), vol. 46, pages 87 - 93
    - BOEHM T ET AL., "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance", NATURE, (1997), vol. 390, doi:doi:10.1038/37126, pages 404 - 407, XP000857413

DOI:   http://dx.doi.org/10.1038/37126
    - ANDRADE MA ET AL., "Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network", PROTEIN ENG., (1993), vol. 6, pages 383 - 390
    - KRANENBURG O; BOUMA B; KROON-BATENBURG LM ET AL., "Tissue-type plasminogen activator is a multiligand cross-beta structure receptor", CURR BIOL., (2002), vol. 12, pages 1833 - 1839
    - VAN ZONNEVELD AJ; VEERMAN H; PANNEKOEK H., "On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid.", J BIOL CHEM., (1986), vol. 261, pages 14214 - 14218, XP001317647
    - LEVINE H, III, "Quantification of beta-sheet amyloid fibril structures with thioflavin T", METHODS ENZYMOL., (1999), vol. 309, doi:doi:10.1016/S0076-6879(99)09020-5, pages 274 - 284, XP002930179

DOI:   http://dx.doi.org/10.1016/S0076-6879(99)09020-5
    - KRANENBURG O ET AL., "Inhibition of cychn- dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells", J CELL BIOL., (1995), vol. 131, pages 227 - 234
    - JOHANNESSEN M; DINESS V; PINGEL K ET AL., "Fibrin affinity and clearance of t-PA deletion and substitution analogues", THROMB HAEMOST., (1990), vol. 6, no. 3, pages 54 - 59
    - GEBBINK MF ET AL., "Cell surface expression of receptor protein tyrosine phosphatase RPTP mu is regulated by cell-cell contact", J CELL BIOL., (1995), vol. 131, pages 251 - 260
    - STEWART RJ; FREDENBURGH JC; WEITZ JI, "Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E", J BIOL CHEM., (1998), vol. 273, pages 18292 - 18299
    - TUCKER HM; KIHIKO M; CALDWELL JN ET AL., "The plasmin system is induced by and degrades amyloid-beta aggregates", J NEUROSCI., (2000), vol. 20, pages 3937 - 3946, XP002217265
    - TUCKER HM ET AL., "Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition", J NEUROCHEM., (2000), vol. 75, pages 2172 - 2177
    - REDLITZ A ET AL., "Plasma carboxypeptidases as regulators of the plasminogen system", J CLIN INVEST., (1995), vol. 96, doi:doi:10.1172/JCI118315, pages 2534 - 2538, XP001033705

DOI:   http://dx.doi.org/10.1172/JCI118315
    - HAYDEN MR; TYAGI SC., ""A" is for amylin and amyloid in type 2 diabetes mellitus", JOP, (2001), vol. 2, pages 124 - 139
    - MORIARTY DF; RALEIGH DP., "Effects of sequential proline substitutions on amyloid formation by human amylin20-29", BIOCHEMISTRY, (1999), vol. 38, doi:doi:10.1021/bi981658g, pages 1811 - 1818, XP002249402

DOI:   http://dx.doi.org/10.1021/bi981658g
    - SAISHOJI T; HIGASHI T; IKEDA K ET AL., "Advanced glycation end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells", BIOCHEM BIOPHYS RES COMMUN., (1995), vol. 217, pages 278 - 285
    - NGUYEN JT; INOUYE H; BALDWIN MA ET AL., "X-ray diffraction of scrapie prion rods and PrP peptides", J MOL BIOL., (1995), vol. 252, pages 412 - 422
    - MOTOMIYA Y ET AL., "N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis", KIDNEY INT., (1998), vol. 54, pages 1357 - 1366
    - SADY C; JIANG CL; CHELLAN P ET AL., "Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins", BIOCHIM BIOPHYS ACTA, (2000), vol. 1481, doi:doi:10.1016/S0167-4838(00)00133-3, pages 255 - 264, XP004279007

DOI:   http://dx.doi.org/10.1016/S0167-4838(00)00133-3
    - SHIBAYAMA Y ET AL., "Zinc- dependent activation of the plasma ki:nin.-forming cascade by aggregated beta amyloid protein", CLIN IMMUNOL., (1999), vol. 90, pages 89 - 99
    - BENNETT WF; PAONI NF; KEYT BA ET AL., "High resolution analysis of functional determinants on human tissue-type plasminogen activator", J BIOL CHEM., (1991), vol. 266, pages 5191 - 5201, XP002053063
    - HORREVOETS AJ ET AL., "The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis", J BIOL CHEM., (1994), vol. 269, pages 12639 - 12644, XP002235245
    - MATSUKA YV ET AL., "The NH2-terminal fibrin-binding site of fibronectin is formed by interacting fourth and fifth finger domains. Studies with recombinant finger fragments expressed in Escherichia coli", J BIOL CHEM., (1994), vol. 269, pages 9539 - 9546, XP000887290
    - BECKMANN R ET AL., "Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator", J BIOL CHEM., (1991), vol. 266, pages 2227 - 2232
    - O'NUALLAIN B; WETZEL R., "Conformational Abs recognizing a generic amyloid fibril epitope", PROC NATL ACAD SCI U S A., (2002), vol. 99, doi:doi:10.1073/pnas.022662599, pages 1485 - 1490, XP002211263

DOI:   http://dx.doi.org/10.1073/pnas.022662599
    - KAYED R; HEAD E; THOMPSON JL ET AL., "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis", SCIENCE, (2003), vol. 300, pages 486 - 489
    - CUTLER P; BROWN F; CAMILLERI P ET AL., "The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid", FEBS LETT., (1997), vol. 412, pages 341 - 345
    - STERN RA; TROJANOWSKI JQ; LEE VM., "Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood", FEBS LETT., (1990), vol. 264, doi:doi:10.1016/0014-5793(90)80760-G, pages 43 - 47, XP001153493

DOI:   http://dx.doi.org/10.1016/0014-5793(90)80760-G
    - DOWNING AK; DRISCOLL PC; HARVEY TS ET AL., "Solution structure of the fibrin binding finger domain of tissue-type plasminogen activator determined by 1H nuclear magnetic resonance", J MOL BIOL., (1992), vol. 225, doi:doi:10.1016/0022-2836(92)90403-7, pages 821 - 833, XP024022070

DOI:   http://dx.doi.org/10.1016/0022-2836(92)90403-7
    - SMITH BO ET AL., "The solution structure and backbone dynamics of the fibronectin type I and epidermal growth factor-like pair of modules of tissue-type plasminogen activator", STRUCTURE, (1995), vol. 3, doi:doi:10.1016/S0969-2126(01)00217-9, pages 823 - 833, XP004587895

DOI:   http://dx.doi.org/10.1016/S0969-2126(01)00217-9
    - WILLIAMS MJ ET AL., "Solution structure of a pair of fibronectin type 1 modules with fibrin binding activity", J MOL BIOL., (1994), vol. 235, doi:doi:10.1006/jmbi.1994.1083, pages 1302 - 1311, XP024008617

DOI:   http://dx.doi.org/10.1006/jmbi.1994.1083
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.